Hidrovias do Brasil Valuation
Is HBSA3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HBSA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HBSA3 (R$3.2) is trading below our estimate of fair value (R$13.48)
Significantly Below Fair Value: HBSA3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HBSA3?
Key metric: As HBSA3 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is HBSA3's PS Ratio? | |
|---|---|
| PS Ratio | 1.5x |
| Sales | R$1.65b |
| Market Cap | R$2.51b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | 24.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does HBSA3's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
LOGN3 Log-In Logística Intermodal | 0.8x | 6.3% | R$2.2b |
LUXM4 Trevisa Investimentos | 1.8x | n/a | R$263.5m |
MOVI3 Movida Participações | 0.2x | 13.1% | R$2.4b |
TGMA3 Tegma Gestão Logística | 1.1x | 1.8% | R$2.1b |
HBSA3 Hidrovias do Brasil | 1.5x | 17.5% | R$2.5b |
Price-To-Sales vs Peers: HBSA3 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does HBSA3's PS Ratio compare vs other companies in the Global Shipping Industry?
| 9 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 9 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: HBSA3 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Global Shipping industry average (1.2x).
Price to Sales Ratio vs Fair Ratio
What is HBSA3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.5x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: HBSA3 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | R$3.20 | R$4.92 +53.6% | 19.3% | R$6.00 | R$3.60 | n/a | 6 |
| Nov ’25 | R$3.07 | R$4.92 +60.2% | 19.3% | R$6.00 | R$3.60 | n/a | 6 |
| Oct ’25 | R$3.38 | R$4.92 +45.5% | 19.3% | R$6.00 | R$3.60 | n/a | 6 |
| Sep ’25 | R$3.49 | R$4.95 +41.8% | 18.4% | R$6.00 | R$3.60 | n/a | 6 |
| Aug ’25 | R$3.40 | R$4.95 +45.6% | 18.4% | R$6.00 | R$3.60 | n/a | 6 |
| Jul ’25 | R$3.70 | R$5.05 +36.5% | 16.5% | R$6.00 | R$3.60 | n/a | 6 |
| Jun ’25 | R$4.01 | R$5.16 +28.7% | 15.2% | R$6.00 | R$4.00 | n/a | 5 |
| May ’25 | R$4.39 | R$8.56 +95.0% | 84.7% | R$23.00 | R$4.00 | n/a | 5 |
| Apr ’25 | R$4.28 | R$5.24 +22.4% | 14.4% | R$6.00 | R$4.20 | n/a | 5 |
| Mar ’25 | R$3.74 | R$5.28 +41.2% | 13.3% | R$6.00 | R$4.40 | n/a | 5 |
| Feb ’25 | R$3.68 | R$5.28 +43.5% | 13.3% | R$6.00 | R$4.40 | n/a | 5 |
| Jan ’25 | R$3.94 | R$5.30 +34.5% | 13.7% | R$6.10 | R$4.40 | n/a | 5 |
| Dec ’24 | R$3.74 | R$5.46 +46.0% | 11.1% | R$6.10 | R$4.40 | n/a | 5 |
| Nov ’24 | R$3.74 | R$5.62 +50.3% | 6.5% | R$6.10 | R$5.20 | R$3.07 | 5 |
| Oct ’24 | R$4.58 | R$4.66 +1.7% | 15.7% | R$5.50 | R$3.60 | R$3.38 | 5 |
| Sep ’24 | R$4.09 | R$4.05 -1.0% | 19.7% | R$5.20 | R$3.00 | R$3.49 | 6 |
| Aug ’24 | R$3.99 | R$4.02 +0.7% | 18.8% | R$5.00 | R$3.00 | R$3.40 | 6 |
| Jul ’24 | R$3.18 | R$4.02 +26.3% | 18.8% | R$5.00 | R$3.00 | R$3.70 | 6 |
| Jun ’24 | R$3.30 | R$3.62 +9.7% | 10.2% | R$4.00 | R$3.00 | R$4.01 | 5 |
| May ’24 | R$2.56 | R$3.62 +41.3% | 9.4% | R$4.00 | R$3.00 | R$4.39 | 6 |
| Apr ’24 | R$2.15 | R$3.53 +64.3% | 8.3% | R$4.00 | R$3.00 | R$4.28 | 6 |
| Mar ’24 | R$1.87 | R$3.74 +100.2% | 15.5% | R$5.00 | R$3.00 | R$3.74 | 7 |
| Feb ’24 | R$2.23 | R$3.74 +67.8% | 15.5% | R$5.00 | R$3.00 | R$3.68 | 7 |
| Jan ’24 | R$2.26 | R$3.84 +70.0% | 14.8% | R$5.00 | R$3.00 | R$3.94 | 7 |
| Dec ’23 | R$2.59 | R$4.07 +57.2% | 17.8% | R$5.20 | R$3.00 | R$3.74 | 7 |
| Nov ’23 | R$2.91 | R$4.07 +39.9% | 17.8% | R$5.20 | R$3.00 | R$3.74 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.